DEFA14A: Neumora Therapeutics Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote

Neumora Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, with proposals including the election of two Class I directors and ratification of Ernst & Young LLP as the independent auditor.

Summary

• Neumora Therapeutics has scheduled its 2024 Annual Meeting of Stockholders for June 13, 2024, at 8:30 AM EDT.
• The meeting will be held virtually at www.virtualshareholdermeeting.com/NMRA2024.
• Stockholders are invited to vote on key proposals, including the election of two Class I directors (Henry O. Gosebruch and Kristina Burow) to serve until the 2027 annual meeting.
• Another proposal involves ratifying the appointment of Ernst & Young LLP as the company's independent auditor for the year ending December 31, 2024.
• Proxy materials, including the Notice and Proxy Statement and 10-K Wrap, are available online at www.ProxyVote.com.
• Stockholders can request a free paper or email copy of these materials before May 30, 2024, by visiting www.ProxyVote.com, calling 1-800-579-1639, or emailing sendmaterial@proxyvote.com.
• The deadline to vote is June 12, 2024, at 11:59 PM ET.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral but necessary corporate process. The sentiment is moderately positive as it reflects ongoing governance and shareholder engagement.

Positives

• The company is providing multiple avenues for stockholders to access proxy materials and vote, including online, phone, and email.
• The virtual meeting format allows for broader participation from stockholders.

Future Outlook

The document outlines the standard procedures for an annual meeting, focusing on governance and compliance.

Industry Context

This announcement is a routine part of corporate governance, ensuring stockholders have the opportunity to vote on important company matters.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction through voting.
• The outcome of the votes will impact the composition of the Board of Directors and the selection of the independent auditor.

Next Steps

• Stockholders to review proxy materials and vote on the proposals.
• Company to hold the Annual Meeting on June 13, 2024.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Auditor, Voting, Neumora Therapeutics